Mechanisms of Disease R/R in CAR-T for Hematologic Malignancies

Part of paid clinical trials in Durham, North Carolina.

Sponsor
Duke University
Study ID
NCT05397132
Status
Recruiting
Apply to this trial

Conditions

  • Hematologic Malignancy

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Blood draw — GENETIC
    Patients will provide a blood draw for research and repository

Study Details

The primary purpose of this IRB protocol is to perform immune profiling focusing on the measurement of Myeloid derived suppressor cells (MDSCs) over time in patients receiving Chimeric antigen receptor (CAR) T therapy and determine the correlation between immune profile and disease relapse/resistance in CAR T therapy.

Key Dates

Start date
May 27, 2022
Status verified
May 2025
Primary completion
Nov 1, 2026
Completion
Nov 1, 2026

Study Design

Enrollment
50 participants (estimated)

Primary Outcome Measure

Correlation between change in immune profile and disease relapse/resistance in CAR T therapy [ Time Frame: before CAR T therapy, 1 week after CAR T and then every 3-6 months, and at the time of disease relapse (up to 5 years) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Duke UniversityDurhamNorth Carolina27710
Cristina Gasparetto, MD
[email protected]
919-668-1017

Find similar trials in Durham, NC

By research site
Duke University· Durham, NC

Related Studies